Clifford Chance

Paul’s recent experience* includes advising:

• Eli Lilly and Company (NYSE: LLY) in its tender offer and acquisition of Sigilon Therapeutics, Inc., for a purchase price of US$14.92 per share in cash (approximately US$34.6 million), plus a contingent value right that entitled the Sigilon stockholders to receive up to an additional US$111.64 in cash upon the achievement of future milestones, for an aggregate purchase price of up to approximately US$309.6 million.
• Goldman Sachs & Co. LLC, Cowen and Company, LLC and Guggenheim Securities, LLC, as joint book-running managers of a US$230 million upsized underwritten public offering of common stock by Revance Therapeutics, Inc. (Nasdaq: RVNC), which included the full exercise of the option to purchase additional shares by Goldman Sachs, Cowen and Guggenheim. Revance is a biotechnology company focused on elevating patient and physician experiences through the development, acquisition and commercialization of innovative aesthetic and therapeutic offerings.
• Zurn Water Solutions Corp. (NYSE: ZWS) in its acquisition of Elkay Manufacturing Co. in an all-stock transaction that valued Elkay at US$1.56 billion. The deal required the filing of a Form S-4. Zurn is a market leader in smart, sustainable water solutions and products.
• 23andMe Holding Co. (Nasdaq: ME) in its filing of a US$500 million shelf registration statement on Form S-3 and the establishment of an at-the-market (ATM) public offering program for up to US$150 million of Class A common stock.
• PTC Therapeutics, Inc. (Nasdaq: PTCT) in its filing of a resale registration statement on Form S-3ASR.
• Selina Hospitality PLC (Nasdaq: SLNA), a global hospitality brand, in its merger with BOA Acquisition Corp., a publicly traded special purpose acquisition company.
• Rexnord Corp. in its merger with Regal Beloit Corp., under which Rexnord separated its Process & Motion Control (PMC) segment by way of a tax-free spin-off to Rexnord shareholders and then was combined with Regal in a Reverse Morris Trust (RMT) transaction. The RMT transaction included the filing of a Form S-4. With the addition of PMC, Regal’s 2020 pro forma revenue was approximately US$4.1 billion, and the resulting merger resulted in a US$10 billion public PMC business (NYSE: RRX).
• Cowen & Company, LLC as sales agent in a new US$150 million at-the-market (ATM) public offering of common shares of Revance Therapeutics Inc. (Nasdaq: RVNC) pursuant to a shelf registration statement on Form S-3.
• uniQure N.V. (Nasdaq: QURE), a clinical-stage biotechnology company, in its registered US$250 million follow-on public offering of ordinary shares, which included the full exercise of the underwriters’ option to purchase additional shares.

*Prior to joining Clifford Chance in 2023.